SlideShare ist ein Scribd-Unternehmen logo
1 von 34
Downloaden Sie, um offline zu lesen
ProgramStrategies to Reduce Post-
PartumHemorrhage and Pre-
Eclampsia/Eclampsia: A practical
review of research findings
John Varallo, Khatidja Naithani, & Rehana Gubin
on behalf of the MCHIPMaternal Health Team
Lunchtime Roundtable
CORE Group Spring Meeting 2013
1
Integrative reviews on PPH and PE/E
recently published in BMC Pregnancy &
Childbirth
Side effects of magnesium
sulfate forPE/E management
3
IS MgSO4 A
DANGEROUS
DRUG?
What is PE/E?
 Pre-eclampsia / eclampsia (PE/E) is a life-
threatening multisystem disorder
 A common cause of maternal and perinatal
morbidity and mortality
 9% of maternal deaths in Asia / Africa
 25% of maternal deaths in Latin America / Caribbean
 Global focus on prevention, detection and
management strategies
 Expansion of use of MgSO4
4
Magnesiumsulfate (MgSO4)
 Drug of choice for prevention and management
of eclamptic seizures
5
 Significantly more effective
than diazepam or
phenytoin in preventing
seizures in PE/E
 MCETG, Magpie, Cochrane
 Use re-affirmed in WHO
Clinical Guidelines 2011
However…
 Universal and consistent use of MgSO4 has
been very slow to take hold
6
Fearthat MgSO4 is highly toxic
 “We all know of many cases of death due to
MgSO4 overdose.”
 “We mustn’t let lower level workers use it due to
toxicity”
 “Hospitals and facilities should have calcium
gluconate available to manage overdose”
 “Magnesium sulfate is a dangerous drug!”
7
Potential Side Effects of MgSO4
 Minor - feeling of warmth, flushing, nausea
and vomiting, muscle weakness,
somnolence, dizziness, and irritation at the
injection site
 More serious
 Loss of patellar reflex (typically at a serum
concentration of >8 -10 mEq/L)
 Respiratory depression (>15 mEq/L)
8
Research Questions
 Incidences of side effects of absent
patellar reflex and respiratory
depression?
 Frequency of use of Ca++
gluconate to counteract the effects
of MgSO4 in response to detected
side effects?
9
 Frequency of skipped or delayed doses of MgSO4 in
response to development of side effects?
 How many maternal deaths of women with severe PE/E
have been reported to be attributed to toxicity of MgSO4
rather than from manifestations of the underlying
disease?
Results Overview
Overall Outcome Rates all studies in 9556 subjects
Affected
Patella
Reflex
Respiratory
Depression
Oliguria Skipped
Dose
Calcium
Gluconate
use
Incidence 1.6% 1.3% 2.5% 3.6% 0.2%
One maternal death reported by authors as due to MgSO4
10
Results:
Maternal death attributed to MgSO4
0.01%
1 / 9556 women in all groups
Total maternal deaths (all causes) 91 / 9556
Authors reported that cause was severe respiratory
depression.
 Woman’s serum magnesium was 24 mEq/L,
which is well above therapeutic level
 Death reported in small trial with 54 participants
 Magpie trial (n= 5055) had no deaths
11
Estimates of clinical impact
Affected
Patellar
Reflex
Respiratory
depression
Skipped or
delayed dose
Calcium
gluconate use
Incidence 1.6% 1.3% 3.6% 0.18%
NNH:
Number
needed to
harm
61 77 27 555
Scenario: Hospital delivers 5000 women annually. Assuming 5% rate of PE/E,
250 women annually will require MgSO4 in treatment
Frequency of
1 case
2.9 months 3.7 months 1.3 months 26.7 months
12
Routine Monitoring of MgSO4 Use
 Neurologic status (level of alertness and
patellar reflexes)
 Respiratory rate
 Urinary output (Oliguria is element of disease
process)
 Typical management of more serious side
effects: ↑ monitoring, delay next dose or
suspend MgSO4 therapy, counteraction with
calcium gluconate
13
14
Monitoring of MgSO4 Use
Conclusions:
MgSO4 is a safe drug
Findings indicate:
Low incidence of severe side effects (1-2%)
When adverse effects occur, delaying the next
scheduled dose is generally sufficient to mitigate
the effect.
Maternal mortality directly attributable to use of
MgSO4 was extremely rare.
15
MgSO4 is NOT a dangerous drug
Conclusions:
Policy and Practice
 Severe PE/E should be diagnosed and treated
with appropriate drugs,
 MgSO4 is anticonvulsant of choice
 Women under treatment with MgSO4 need
reasonable vigilance for side effects
 Simple protocols should be in place to manage
side effects
 All clinical leaders in maternal health should guide
adoption / use of MgSO4 as standard of care
 Including ensuring adequate supply of MgSO4
16
Community-based distribution of
misoprostol forPPHprevention
26
Photo: Save the Children
What is PPH?
 Blood loss >500mL in the
first 24 hours after
delivery
 Severe PPH is loss of
1000mL or more.
 Accurately quantifying
blood loss is difficult in
most clinical or home
settings.
 Many severely anemic
women cannot tolerate
even 500 mL blood loss
PPH: Leading Cause of Maternal
Mortality
 Hemorrhage is a leading
cause of maternal deaths
 35% of global
maternal deaths
 estimated 132,000
maternal deaths
 14 million women in
developing countries
experience PPH—26
women every minute
34%
31%
21%
0%
5%
10%
15%
20%
25%
30%
35%
40%
Africa Asia Latin America & the
Caribbean
Sources: Khan et al., 2006; POPPHI, 2009;
Taking Stock of Maternal, Newborn and Child
Survival, 2000–2010 Decade Report
PPHPrevention
1. Active management of the third stage of labor
(AMTSL)
 During deliveries with a skilled provider
 Prevents immediate PPH
 Associated with almost 60% reduction in PPH
occurrence
1. Misoprostol
 During home births without a skilled provider
 Community-based counseling and distribution of
misoprostol
Global Context
 Inclusion on 2011 WHO Essential Drug
List
 Qualifications in 2012 WHO
Recommendations
 “If a skilled attendant is not present, and
oxytocin is not available (such as at an
unattended home birth), lay health
workers should administer 600 mcg
of oral misoprostol.”
 “There is insufficient evidence to
recommend the antenatal distribution of
misoprostol to pregnant women for self-
administration for the prevention of
PPH.”
Evidentiary Gaps
2012 Cochrane review noted
need for more information
on:
 Feasibility of misoprostol
reaching the end-user (coverage)
 Patient outcomes after use
 Adverse effects from misuse
 Outcomes useful to
policymakers, such as resource
utilization
Research Questions
 What is the range of implementation
strategies for programs distributing misoprostol
for the prevention of PPH at home births?
 Which strategies achieve high distribution
and coverage rates?
 Do misoprostol programs adversely affect
facility birth rates?
 What is the incidence of adverse outcomes for
misoprostol users, especially of mistimed
administration before birth?
33
Country # enrolled # tookmiso
Afghanistan 2 039 1 350
Bangladesh 53 897 46 561
Bangladesh 1 009 884
Bangladesh 19 497 9 228
Ethiopia 500 485
Gambia 630 630
Ghana 5 345 1 261
India 812 809
Indonesia 1 322 999
Kenya 3 844 1 084
Mozambique 11 927 4 781
Nepal 18 761 13 969
Nigeria 1 875 1 421
Pakistan 534 533
Pakistan 872 678
Tanzania 12 511 1 826
Zambia 5 574 233
Zambia 31 315 Not reported
 18 studies or programs
included
 Not all enrolled women
received misoprostol
 86,732 women took
misoprostol
 12,615 were followed-up
 Results presented based on
number of women on whom
condition was reported (i. e . ,
data is inco m ple te )
Results Overview
34
When was misoprostol distributed?
Timing of Distribution
# programs
(n =18)
% of
programs
Any antenatal care visit (>12
weeks)
4 22.2%
Late pregnancy home visit
(28–32 weeks)
4 22.2%
Late pregnancy antenatal
care visit (>28 weeks)
3 16.7%
At home birth 10 55.6%
35
Who distributed the misoprostol?
Distributing Cadre
# programs (n
=18)
% of
programs
Community health worker 5 27.8%
Traditional birth attendant 7 38.9%
Health workers/ANC providers 8 44.4%
Other (FP field worker,
community drug keeper)
2 11.1%
36
Who administered the misoprostol?
Person Administering
# programs (n
=18)
% of
programs
Self-administered 11 61.1%
Traditional birth attendant 9 50.0%
Community health worker 1 5.6%
SBA or semi-skilled health
worker
3 16.7%
37
 Distribution rates: 21.0% – 96.6%
 % of women in target population who received misoprostol
 Coverage rates: 16.2% – 93.8%
 % of women who delivered at home who used misoprostol
 Only 10 of the 18 programs provided sufficient
information to reliably calculate coverage rates
Measuring “Success”: Distribution
and Coverage Rates
38
Distribution Timing  Distributing Cadre Administration Method 
ANC Distribution
Home Visit
(late
pregnancy)
At home
birth
Comm-
unity
health
worker
Traditional
birth
attendant
Health
worker/
ANC
provider
Self
Traditional
birth
attendant
SBA or
semi-
skilled
health
worker
Any visit Late visit
Distribution
Rate orRate
Range
22.5–
49.1%
21.0–
26.7%
 54.5–
96.6% 
22.5–
83.6%
54.5–
96.6%
25.9–
86.5%
21.0–
49.1%
21.0–
96.6%
25.9–
86.5%
22.5%
Coverage
Rate orRate
Range
16.8–
65.9%
16.2–
35.9%
55.7–93.8%
16.8–
73.5%
87.9–
93.8%
35.9–
73.5%
16.2–
65.9% 
16.2–
93.8%
35.9–
73.5%
16.8% 
Distribution & Coverage Rates by
Implementation Strategy
Distribution of misoprostol by community workers (TBAs or
CHWs) during home visits late in pregnancy achieved greatest
distribution and coverage, potentially more than double the
coverage achieved by programs where distribution was through
health workers or as a part of ANC services.
39
 Three programs (Nepal,
Afghanistan and Zambia)
reported the change in facility
birth rate in program areas
 Programs were not powered to
measure a statistically
significant change
 In these three programs, facility
birth rates increasedin the
target areas
No Adverse Change in Facility Birth
Rates
40
Low Incidence of Adverse Outcomes
Outcomes # of occurrences
(total # of women taking
misoprostol at home
births)
Frequency
(Range)
Administration Priorto
Birth
7 (12 615) 0.06% (0%–0.23%)
Total Maternal Deaths 51 (86 732) 0.06% (0%–1.72%)
Deaths due to PPH 24 (86 732) 0.03% (0.00%–0.16%)
Deaths attributed to
misoprostol
0 (86 732) 0%
Perceived PPH 194 (72 534) 0.3% (0%–8.9%)
Otheradverse outcomes
requiring hospital referral 27 (86 732) 0.03% (0%–0.3%)
41
 If programs want high coverage, they should design
programs with population coverage in mind, considering:
 In-home distribution, by CHWs or TBAs, and
 Self-administration with adequate education & counseling.
 Mistimed self-administration is rare and should not be a
reason to limit program development.
 Limited available data suggest that programs do not counter
national strategies to promote facility-based births.
Ourreview suggests that ANC-only distribution
achieves 50% less coverage, so it likely does not
protect those who need coverage the most.
Conclusions forPractice
42
Continuing ProgramEvidence
Thank you!
www.mchip.net
Follow us on:

Weitere ähnliche Inhalte

Was ist angesagt?

Optimizing The outcome of Threatened Abortion Dr Sharda Jain
Optimizing The outcome of Threatened Abortion  Dr Sharda Jain Optimizing The outcome of Threatened Abortion  Dr Sharda Jain
Optimizing The outcome of Threatened Abortion Dr Sharda Jain Lifecare Centre
 
Patient centered contraception
Patient centered contraceptionPatient centered contraception
Patient centered contraceptionSagarika Roy
 
Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation
Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation  Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation
Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation MEASURE Evaluation
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineAboubakr Elnashar
 
Unexplained infertility astrakhan webinar copy
Unexplained infertility astrakhan webinar   copyUnexplained infertility astrakhan webinar   copy
Unexplained infertility astrakhan webinar copyAkram Shalabi
 
Boosting Endogenous Progesterone
Boosting Endogenous ProgesteroneBoosting Endogenous Progesterone
Boosting Endogenous ProgesteroneSujoy Dasgupta
 
Long acting reversible contraception
Long acting reversible contraceptionLong acting reversible contraception
Long acting reversible contraceptionAlia Syarmila
 
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...Lifecare Centre
 
Maternal health care situation in Bangladesh: Status and utilization of healt...
Maternal health care situation in Bangladesh: Status and utilization of healt...Maternal health care situation in Bangladesh: Status and utilization of healt...
Maternal health care situation in Bangladesh: Status and utilization of healt...Abdullah Maswood
 
Ivf necessary element in gynaecology
Ivf necessary element in gynaecologyIvf necessary element in gynaecology
Ivf necessary element in gynaecologydrhemantzaveri
 
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleClomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleDr.Laxmi Agrawal Shrikhande
 
Prima IVF poor responders
Prima IVF  poor respondersPrima IVF  poor responders
Prima IVF poor respondersHesham Al-Inany
 
Bangladesh Maternal Mortality and Health Care Survey 2016
Bangladesh Maternal Mortality and Health Care Survey 2016Bangladesh Maternal Mortality and Health Care Survey 2016
Bangladesh Maternal Mortality and Health Care Survey 2016MEASURE Evaluation
 

Was ist angesagt? (20)

Mirena: AN ALTERNATIVE TO HYSTERECTOMY
Mirena: AN ALTERNATIVE TO HYSTERECTOMYMirena: AN ALTERNATIVE TO HYSTERECTOMY
Mirena: AN ALTERNATIVE TO HYSTERECTOMY
 
Optimizing The outcome of Threatened Abortion Dr Sharda Jain
Optimizing The outcome of Threatened Abortion  Dr Sharda Jain Optimizing The outcome of Threatened Abortion  Dr Sharda Jain
Optimizing The outcome of Threatened Abortion Dr Sharda Jain
 
Fibroid & infertility
Fibroid & infertilityFibroid & infertility
Fibroid & infertility
 
Low amh what next
Low amh  what nextLow amh  what next
Low amh what next
 
Abortion
AbortionAbortion
Abortion
 
Patient centered contraception
Patient centered contraceptionPatient centered contraception
Patient centered contraception
 
Complete Guide To Infertility
Complete Guide To InfertilityComplete Guide To Infertility
Complete Guide To Infertility
 
Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation
Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation  Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation
Prevalence of Maternal Morbidity in Bangladesh, 2016: A National Estimation
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Unexplained infertility astrakhan webinar copy
Unexplained infertility astrakhan webinar   copyUnexplained infertility astrakhan webinar   copy
Unexplained infertility astrakhan webinar copy
 
Boosting Endogenous Progesterone
Boosting Endogenous ProgesteroneBoosting Endogenous Progesterone
Boosting Endogenous Progesterone
 
Long acting reversible contraception
Long acting reversible contraceptionLong acting reversible contraception
Long acting reversible contraception
 
Emergency Contraception-Whats New?
Emergency Contraception-Whats New?Emergency Contraception-Whats New?
Emergency Contraception-Whats New?
 
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda ...
 
Maternal health care situation in Bangladesh: Status and utilization of healt...
Maternal health care situation in Bangladesh: Status and utilization of healt...Maternal health care situation in Bangladesh: Status and utilization of healt...
Maternal health care situation in Bangladesh: Status and utilization of healt...
 
Ivf necessary element in gynaecology
Ivf necessary element in gynaecologyIvf necessary element in gynaecology
Ivf necessary element in gynaecology
 
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleClomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
 
UOG Journal Club: Dydrogesterone versus progesterone for luteal-phase support...
UOG Journal Club: Dydrogesterone versus progesterone for luteal-phase support...UOG Journal Club: Dydrogesterone versus progesterone for luteal-phase support...
UOG Journal Club: Dydrogesterone versus progesterone for luteal-phase support...
 
Prima IVF poor responders
Prima IVF  poor respondersPrima IVF  poor responders
Prima IVF poor responders
 
Bangladesh Maternal Mortality and Health Care Survey 2016
Bangladesh Maternal Mortality and Health Care Survey 2016Bangladesh Maternal Mortality and Health Care Survey 2016
Bangladesh Maternal Mortality and Health Care Survey 2016
 

Ähnlich wie Program Strategies to Reduce Post-Partum Hemorrhage and Pre-Eclampsia_John Varallo_Khatidja Naithani_Rehana Gubin_4.24.13

MgSO4
MgSO4MgSO4
MgSO4SoM
 
2 good afr health sci
2 good afr health sci2 good afr health sci
2 good afr health sciDavid Deegbe
 
Therapeutic startegies for human papillomavirus infection and associated cancers
Therapeutic startegies for human papillomavirus infection and associated cancersTherapeutic startegies for human papillomavirus infection and associated cancers
Therapeutic startegies for human papillomavirus infection and associated cancersAdeniyiAkiseku
 
Adjuvants in ART.pptx
Adjuvants in ART.pptxAdjuvants in ART.pptx
Adjuvants in ART.pptxDeepekaTS
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labourlimgengyan
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labourlimgengyan
 
Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14
Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14
Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14CORE Group
 
maternalmortality2-120209044035-phpapp01 (1).pdf
maternalmortality2-120209044035-phpapp01 (1).pdfmaternalmortality2-120209044035-phpapp01 (1).pdf
maternalmortality2-120209044035-phpapp01 (1).pdfhamzakhattak13
 
Injectable contraceptives
Injectable contraceptivesInjectable contraceptives
Injectable contraceptivesraj kumar
 
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...Lifecare Centre
 
Introduction to malaria in pregnancy
Introduction to malaria in pregnancyIntroduction to malaria in pregnancy
Introduction to malaria in pregnancystompoutmalaria
 
Ulipristal MonographUTD
Ulipristal MonographUTDUlipristal MonographUTD
Ulipristal MonographUTDJade Abudia
 
CURRECT MRM ARTICAL
CURRECT MRM  ARTICALCURRECT MRM  ARTICAL
CURRECT MRM ARTICALDr. Lutfa
 
Antibiotic in incomplete abortion by liza tarca, md
Antibiotic in incomplete abortion by liza tarca, mdAntibiotic in incomplete abortion by liza tarca, md
Antibiotic in incomplete abortion by liza tarca, mdLiza Tarca
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilBharati Dhorepatil
 
General considerations and maternal evaluation
General considerations and maternal evaluationGeneral considerations and maternal evaluation
General considerations and maternal evaluationDR MUKESH SAH
 
DGH Lecture Series: Michael Chung
DGH Lecture Series: Michael ChungDGH Lecture Series: Michael Chung
DGH Lecture Series: Michael ChungUWGlobalHealth
 
Maternal Mortality
Maternal MortalityMaternal Mortality
Maternal Mortalitylimgengyan
 
Management of first trimester miscarriage
Management of first trimester miscarriageManagement of first trimester miscarriage
Management of first trimester miscarriageAboubakr Elnashar
 

Ähnlich wie Program Strategies to Reduce Post-Partum Hemorrhage and Pre-Eclampsia_John Varallo_Khatidja Naithani_Rehana Gubin_4.24.13 (20)

MgSO4
MgSO4MgSO4
MgSO4
 
2 good afr health sci
2 good afr health sci2 good afr health sci
2 good afr health sci
 
Therapeutic startegies for human papillomavirus infection and associated cancers
Therapeutic startegies for human papillomavirus infection and associated cancersTherapeutic startegies for human papillomavirus infection and associated cancers
Therapeutic startegies for human papillomavirus infection and associated cancers
 
Adjuvants in ART.pptx
Adjuvants in ART.pptxAdjuvants in ART.pptx
Adjuvants in ART.pptx
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
 
Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14
Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14
Community Midwifery and Prevention of Postpartum Hemorrhage_Kate Brickson_5.8.14
 
maternalmortality2-120209044035-phpapp01 (1).pdf
maternalmortality2-120209044035-phpapp01 (1).pdfmaternalmortality2-120209044035-phpapp01 (1).pdf
maternalmortality2-120209044035-phpapp01 (1).pdf
 
Injectable contraceptives
Injectable contraceptivesInjectable contraceptives
Injectable contraceptives
 
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...
PCOD,How are they different ??Difficulties & Solutions made Easy , Dr. Sharda...
 
Introduction to malaria in pregnancy
Introduction to malaria in pregnancyIntroduction to malaria in pregnancy
Introduction to malaria in pregnancy
 
Ulipristal MonographUTD
Ulipristal MonographUTDUlipristal MonographUTD
Ulipristal MonographUTD
 
CURRECT MRM ARTICAL
CURRECT MRM  ARTICALCURRECT MRM  ARTICAL
CURRECT MRM ARTICAL
 
Antibiotic in incomplete abortion by liza tarca, md
Antibiotic in incomplete abortion by liza tarca, mdAntibiotic in incomplete abortion by liza tarca, md
Antibiotic in incomplete abortion by liza tarca, md
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
 
General considerations and maternal evaluation
General considerations and maternal evaluationGeneral considerations and maternal evaluation
General considerations and maternal evaluation
 
DGH Lecture Series: Michael Chung
DGH Lecture Series: Michael ChungDGH Lecture Series: Michael Chung
DGH Lecture Series: Michael Chung
 
Maternal Mortality
Maternal MortalityMaternal Mortality
Maternal Mortality
 
F04602039047
F04602039047F04602039047
F04602039047
 
Management of first trimester miscarriage
Management of first trimester miscarriageManagement of first trimester miscarriage
Management of first trimester miscarriage
 

Mehr von CORE Group

Presentation_Behar - Private Public Partnerships and CKDu
Presentation_Behar - Private Public Partnerships and CKDuPresentation_Behar - Private Public Partnerships and CKDu
Presentation_Behar - Private Public Partnerships and CKDuCORE Group
 
Presentation_World Vision - Private Public Partnerships and CKDu
Presentation_World Vision - Private Public Partnerships and CKDuPresentation_World Vision - Private Public Partnerships and CKDu
Presentation_World Vision - Private Public Partnerships and CKDuCORE Group
 
Presentation_Wesseling - Private Public Partnerships and CKDu
Presentation_Wesseling - Private Public Partnerships and CKDuPresentation_Wesseling - Private Public Partnerships and CKDu
Presentation_Wesseling - Private Public Partnerships and CKDuCORE Group
 
Presentation_NCDs - Private Public Partnerships and CKDu
Presentation_NCDs - Private Public Partnerships and CKDuPresentation_NCDs - Private Public Partnerships and CKDu
Presentation_NCDs - Private Public Partnerships and CKDuCORE Group
 
Presentation_HRH2030 - Opportunities to optimize and integrate CHW
Presentation_HRH2030 - Opportunities to optimize and integrate CHWPresentation_HRH2030 - Opportunities to optimize and integrate CHW
Presentation_HRH2030 - Opportunities to optimize and integrate CHWCORE Group
 
Presentation_Save the Children - Building Partnerships to Provide Nurturing Care
Presentation_Save the Children - Building Partnerships to Provide Nurturing CarePresentation_Save the Children - Building Partnerships to Provide Nurturing Care
Presentation_Save the Children - Building Partnerships to Provide Nurturing CareCORE Group
 
Presentation_Video - Building Partnerships to provide nurturing care
Presentation_Video - Building Partnerships to provide nurturing carePresentation_Video - Building Partnerships to provide nurturing care
Presentation_Video - Building Partnerships to provide nurturing careCORE Group
 
Presentation_Perez - Building Partnerships to provide nurturing care
Presentation_Perez - Building Partnerships to provide nurturing carePresentation_Perez - Building Partnerships to provide nurturing care
Presentation_Perez - Building Partnerships to provide nurturing careCORE Group
 
Presentation_Robb-McCord - Building Partnerships to provide nurturing care
Presentation_Robb-McCord - Building Partnerships to provide nurturing carePresentation_Robb-McCord - Building Partnerships to provide nurturing care
Presentation_Robb-McCord - Building Partnerships to provide nurturing careCORE Group
 
Presentation_Discussion - Norms Shifting Interventions
Presentation_Discussion - Norms Shifting InterventionsPresentation_Discussion - Norms Shifting Interventions
Presentation_Discussion - Norms Shifting InterventionsCORE Group
 
Presentation_Krieger - Norms Shifting Interventions
Presentation_Krieger - Norms Shifting InterventionsPresentation_Krieger - Norms Shifting Interventions
Presentation_Krieger - Norms Shifting InterventionsCORE Group
 
Presentation_NSI - Norms Shifting Interventions
Presentation_NSI - Norms Shifting InterventionsPresentation_NSI - Norms Shifting Interventions
Presentation_NSI - Norms Shifting InterventionsCORE Group
 
Presentation_Igras - Norms Shifting Interventions
Presentation_Igras - Norms Shifting InterventionsPresentation_Igras - Norms Shifting Interventions
Presentation_Igras - Norms Shifting InterventionsCORE Group
 
Presentation_Petraglia - Norms Shifting Interventions
Presentation_Petraglia - Norms Shifting InterventionsPresentation_Petraglia - Norms Shifting Interventions
Presentation_Petraglia - Norms Shifting InterventionsCORE Group
 
Presentation_Sprinkel - Norms Shifting Interventions
Presentation_Sprinkel - Norms Shifting InterventionsPresentation_Sprinkel - Norms Shifting Interventions
Presentation_Sprinkel - Norms Shifting InterventionsCORE Group
 
Presentation_Tura - Norms Shifting Interventions
Presentation_Tura - Norms Shifting InterventionsPresentation_Tura - Norms Shifting Interventions
Presentation_Tura - Norms Shifting InterventionsCORE Group
 
Presentation_Sacher - Norms Shifting Interventions
Presentation_Sacher - Norms Shifting InterventionsPresentation_Sacher - Norms Shifting Interventions
Presentation_Sacher - Norms Shifting InterventionsCORE Group
 
Innovative Financing Mechanisms and Effective Management of Risk for Partners...
Innovative Financing Mechanisms and Effective Management of Risk for Partners...Innovative Financing Mechanisms and Effective Management of Risk for Partners...
Innovative Financing Mechanisms and Effective Management of Risk for Partners...CORE Group
 
Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...
Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...
Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...CORE Group
 
Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...
Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...
Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...CORE Group
 

Mehr von CORE Group (20)

Presentation_Behar - Private Public Partnerships and CKDu
Presentation_Behar - Private Public Partnerships and CKDuPresentation_Behar - Private Public Partnerships and CKDu
Presentation_Behar - Private Public Partnerships and CKDu
 
Presentation_World Vision - Private Public Partnerships and CKDu
Presentation_World Vision - Private Public Partnerships and CKDuPresentation_World Vision - Private Public Partnerships and CKDu
Presentation_World Vision - Private Public Partnerships and CKDu
 
Presentation_Wesseling - Private Public Partnerships and CKDu
Presentation_Wesseling - Private Public Partnerships and CKDuPresentation_Wesseling - Private Public Partnerships and CKDu
Presentation_Wesseling - Private Public Partnerships and CKDu
 
Presentation_NCDs - Private Public Partnerships and CKDu
Presentation_NCDs - Private Public Partnerships and CKDuPresentation_NCDs - Private Public Partnerships and CKDu
Presentation_NCDs - Private Public Partnerships and CKDu
 
Presentation_HRH2030 - Opportunities to optimize and integrate CHW
Presentation_HRH2030 - Opportunities to optimize and integrate CHWPresentation_HRH2030 - Opportunities to optimize and integrate CHW
Presentation_HRH2030 - Opportunities to optimize and integrate CHW
 
Presentation_Save the Children - Building Partnerships to Provide Nurturing Care
Presentation_Save the Children - Building Partnerships to Provide Nurturing CarePresentation_Save the Children - Building Partnerships to Provide Nurturing Care
Presentation_Save the Children - Building Partnerships to Provide Nurturing Care
 
Presentation_Video - Building Partnerships to provide nurturing care
Presentation_Video - Building Partnerships to provide nurturing carePresentation_Video - Building Partnerships to provide nurturing care
Presentation_Video - Building Partnerships to provide nurturing care
 
Presentation_Perez - Building Partnerships to provide nurturing care
Presentation_Perez - Building Partnerships to provide nurturing carePresentation_Perez - Building Partnerships to provide nurturing care
Presentation_Perez - Building Partnerships to provide nurturing care
 
Presentation_Robb-McCord - Building Partnerships to provide nurturing care
Presentation_Robb-McCord - Building Partnerships to provide nurturing carePresentation_Robb-McCord - Building Partnerships to provide nurturing care
Presentation_Robb-McCord - Building Partnerships to provide nurturing care
 
Presentation_Discussion - Norms Shifting Interventions
Presentation_Discussion - Norms Shifting InterventionsPresentation_Discussion - Norms Shifting Interventions
Presentation_Discussion - Norms Shifting Interventions
 
Presentation_Krieger - Norms Shifting Interventions
Presentation_Krieger - Norms Shifting InterventionsPresentation_Krieger - Norms Shifting Interventions
Presentation_Krieger - Norms Shifting Interventions
 
Presentation_NSI - Norms Shifting Interventions
Presentation_NSI - Norms Shifting InterventionsPresentation_NSI - Norms Shifting Interventions
Presentation_NSI - Norms Shifting Interventions
 
Presentation_Igras - Norms Shifting Interventions
Presentation_Igras - Norms Shifting InterventionsPresentation_Igras - Norms Shifting Interventions
Presentation_Igras - Norms Shifting Interventions
 
Presentation_Petraglia - Norms Shifting Interventions
Presentation_Petraglia - Norms Shifting InterventionsPresentation_Petraglia - Norms Shifting Interventions
Presentation_Petraglia - Norms Shifting Interventions
 
Presentation_Sprinkel - Norms Shifting Interventions
Presentation_Sprinkel - Norms Shifting InterventionsPresentation_Sprinkel - Norms Shifting Interventions
Presentation_Sprinkel - Norms Shifting Interventions
 
Presentation_Tura - Norms Shifting Interventions
Presentation_Tura - Norms Shifting InterventionsPresentation_Tura - Norms Shifting Interventions
Presentation_Tura - Norms Shifting Interventions
 
Presentation_Sacher - Norms Shifting Interventions
Presentation_Sacher - Norms Shifting InterventionsPresentation_Sacher - Norms Shifting Interventions
Presentation_Sacher - Norms Shifting Interventions
 
Innovative Financing Mechanisms and Effective Management of Risk for Partners...
Innovative Financing Mechanisms and Effective Management of Risk for Partners...Innovative Financing Mechanisms and Effective Management of Risk for Partners...
Innovative Financing Mechanisms and Effective Management of Risk for Partners...
 
Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...
Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...
Presentation_Multisectoral Partnerships and Innovations for Early Childhood D...
 
Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...
Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...
Presentation_Jurczynska - Catalyzing Investments in RMNCAH at the Community L...
 

Kürzlich hochgeladen

Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 

Kürzlich hochgeladen (20)

Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 

Program Strategies to Reduce Post-Partum Hemorrhage and Pre-Eclampsia_John Varallo_Khatidja Naithani_Rehana Gubin_4.24.13

  • 1. ProgramStrategies to Reduce Post- PartumHemorrhage and Pre- Eclampsia/Eclampsia: A practical review of research findings John Varallo, Khatidja Naithani, & Rehana Gubin on behalf of the MCHIPMaternal Health Team Lunchtime Roundtable CORE Group Spring Meeting 2013 1
  • 2. Integrative reviews on PPH and PE/E recently published in BMC Pregnancy & Childbirth
  • 3. Side effects of magnesium sulfate forPE/E management 3 IS MgSO4 A DANGEROUS DRUG?
  • 4. What is PE/E?  Pre-eclampsia / eclampsia (PE/E) is a life- threatening multisystem disorder  A common cause of maternal and perinatal morbidity and mortality  9% of maternal deaths in Asia / Africa  25% of maternal deaths in Latin America / Caribbean  Global focus on prevention, detection and management strategies  Expansion of use of MgSO4 4
  • 5. Magnesiumsulfate (MgSO4)  Drug of choice for prevention and management of eclamptic seizures 5  Significantly more effective than diazepam or phenytoin in preventing seizures in PE/E  MCETG, Magpie, Cochrane  Use re-affirmed in WHO Clinical Guidelines 2011
  • 6. However…  Universal and consistent use of MgSO4 has been very slow to take hold 6
  • 7. Fearthat MgSO4 is highly toxic  “We all know of many cases of death due to MgSO4 overdose.”  “We mustn’t let lower level workers use it due to toxicity”  “Hospitals and facilities should have calcium gluconate available to manage overdose”  “Magnesium sulfate is a dangerous drug!” 7
  • 8. Potential Side Effects of MgSO4  Minor - feeling of warmth, flushing, nausea and vomiting, muscle weakness, somnolence, dizziness, and irritation at the injection site  More serious  Loss of patellar reflex (typically at a serum concentration of >8 -10 mEq/L)  Respiratory depression (>15 mEq/L) 8
  • 9. Research Questions  Incidences of side effects of absent patellar reflex and respiratory depression?  Frequency of use of Ca++ gluconate to counteract the effects of MgSO4 in response to detected side effects? 9  Frequency of skipped or delayed doses of MgSO4 in response to development of side effects?  How many maternal deaths of women with severe PE/E have been reported to be attributed to toxicity of MgSO4 rather than from manifestations of the underlying disease?
  • 10. Results Overview Overall Outcome Rates all studies in 9556 subjects Affected Patella Reflex Respiratory Depression Oliguria Skipped Dose Calcium Gluconate use Incidence 1.6% 1.3% 2.5% 3.6% 0.2% One maternal death reported by authors as due to MgSO4 10
  • 11. Results: Maternal death attributed to MgSO4 0.01% 1 / 9556 women in all groups Total maternal deaths (all causes) 91 / 9556 Authors reported that cause was severe respiratory depression.  Woman’s serum magnesium was 24 mEq/L, which is well above therapeutic level  Death reported in small trial with 54 participants  Magpie trial (n= 5055) had no deaths 11
  • 12. Estimates of clinical impact Affected Patellar Reflex Respiratory depression Skipped or delayed dose Calcium gluconate use Incidence 1.6% 1.3% 3.6% 0.18% NNH: Number needed to harm 61 77 27 555 Scenario: Hospital delivers 5000 women annually. Assuming 5% rate of PE/E, 250 women annually will require MgSO4 in treatment Frequency of 1 case 2.9 months 3.7 months 1.3 months 26.7 months 12
  • 13. Routine Monitoring of MgSO4 Use  Neurologic status (level of alertness and patellar reflexes)  Respiratory rate  Urinary output (Oliguria is element of disease process)  Typical management of more serious side effects: ↑ monitoring, delay next dose or suspend MgSO4 therapy, counteraction with calcium gluconate 13
  • 15. Conclusions: MgSO4 is a safe drug Findings indicate: Low incidence of severe side effects (1-2%) When adverse effects occur, delaying the next scheduled dose is generally sufficient to mitigate the effect. Maternal mortality directly attributable to use of MgSO4 was extremely rare. 15 MgSO4 is NOT a dangerous drug
  • 16. Conclusions: Policy and Practice  Severe PE/E should be diagnosed and treated with appropriate drugs,  MgSO4 is anticonvulsant of choice  Women under treatment with MgSO4 need reasonable vigilance for side effects  Simple protocols should be in place to manage side effects  All clinical leaders in maternal health should guide adoption / use of MgSO4 as standard of care  Including ensuring adequate supply of MgSO4 16
  • 17. Community-based distribution of misoprostol forPPHprevention 26 Photo: Save the Children
  • 18. What is PPH?  Blood loss >500mL in the first 24 hours after delivery  Severe PPH is loss of 1000mL or more.  Accurately quantifying blood loss is difficult in most clinical or home settings.  Many severely anemic women cannot tolerate even 500 mL blood loss
  • 19. PPH: Leading Cause of Maternal Mortality  Hemorrhage is a leading cause of maternal deaths  35% of global maternal deaths  estimated 132,000 maternal deaths  14 million women in developing countries experience PPH—26 women every minute 34% 31% 21% 0% 5% 10% 15% 20% 25% 30% 35% 40% Africa Asia Latin America & the Caribbean Sources: Khan et al., 2006; POPPHI, 2009; Taking Stock of Maternal, Newborn and Child Survival, 2000–2010 Decade Report
  • 20. PPHPrevention 1. Active management of the third stage of labor (AMTSL)  During deliveries with a skilled provider  Prevents immediate PPH  Associated with almost 60% reduction in PPH occurrence 1. Misoprostol  During home births without a skilled provider  Community-based counseling and distribution of misoprostol
  • 21. Global Context  Inclusion on 2011 WHO Essential Drug List  Qualifications in 2012 WHO Recommendations  “If a skilled attendant is not present, and oxytocin is not available (such as at an unattended home birth), lay health workers should administer 600 mcg of oral misoprostol.”  “There is insufficient evidence to recommend the antenatal distribution of misoprostol to pregnant women for self- administration for the prevention of PPH.”
  • 22. Evidentiary Gaps 2012 Cochrane review noted need for more information on:  Feasibility of misoprostol reaching the end-user (coverage)  Patient outcomes after use  Adverse effects from misuse  Outcomes useful to policymakers, such as resource utilization
  • 23. Research Questions  What is the range of implementation strategies for programs distributing misoprostol for the prevention of PPH at home births?  Which strategies achieve high distribution and coverage rates?  Do misoprostol programs adversely affect facility birth rates?  What is the incidence of adverse outcomes for misoprostol users, especially of mistimed administration before birth?
  • 24. 33 Country # enrolled # tookmiso Afghanistan 2 039 1 350 Bangladesh 53 897 46 561 Bangladesh 1 009 884 Bangladesh 19 497 9 228 Ethiopia 500 485 Gambia 630 630 Ghana 5 345 1 261 India 812 809 Indonesia 1 322 999 Kenya 3 844 1 084 Mozambique 11 927 4 781 Nepal 18 761 13 969 Nigeria 1 875 1 421 Pakistan 534 533 Pakistan 872 678 Tanzania 12 511 1 826 Zambia 5 574 233 Zambia 31 315 Not reported  18 studies or programs included  Not all enrolled women received misoprostol  86,732 women took misoprostol  12,615 were followed-up  Results presented based on number of women on whom condition was reported (i. e . , data is inco m ple te ) Results Overview
  • 25. 34 When was misoprostol distributed? Timing of Distribution # programs (n =18) % of programs Any antenatal care visit (>12 weeks) 4 22.2% Late pregnancy home visit (28–32 weeks) 4 22.2% Late pregnancy antenatal care visit (>28 weeks) 3 16.7% At home birth 10 55.6%
  • 26. 35 Who distributed the misoprostol? Distributing Cadre # programs (n =18) % of programs Community health worker 5 27.8% Traditional birth attendant 7 38.9% Health workers/ANC providers 8 44.4% Other (FP field worker, community drug keeper) 2 11.1%
  • 27. 36 Who administered the misoprostol? Person Administering # programs (n =18) % of programs Self-administered 11 61.1% Traditional birth attendant 9 50.0% Community health worker 1 5.6% SBA or semi-skilled health worker 3 16.7%
  • 28. 37  Distribution rates: 21.0% – 96.6%  % of women in target population who received misoprostol  Coverage rates: 16.2% – 93.8%  % of women who delivered at home who used misoprostol  Only 10 of the 18 programs provided sufficient information to reliably calculate coverage rates Measuring “Success”: Distribution and Coverage Rates
  • 29. 38 Distribution Timing  Distributing Cadre Administration Method  ANC Distribution Home Visit (late pregnancy) At home birth Comm- unity health worker Traditional birth attendant Health worker/ ANC provider Self Traditional birth attendant SBA or semi- skilled health worker Any visit Late visit Distribution Rate orRate Range 22.5– 49.1% 21.0– 26.7%  54.5– 96.6%  22.5– 83.6% 54.5– 96.6% 25.9– 86.5% 21.0– 49.1% 21.0– 96.6% 25.9– 86.5% 22.5% Coverage Rate orRate Range 16.8– 65.9% 16.2– 35.9% 55.7–93.8% 16.8– 73.5% 87.9– 93.8% 35.9– 73.5% 16.2– 65.9%  16.2– 93.8% 35.9– 73.5% 16.8%  Distribution & Coverage Rates by Implementation Strategy Distribution of misoprostol by community workers (TBAs or CHWs) during home visits late in pregnancy achieved greatest distribution and coverage, potentially more than double the coverage achieved by programs where distribution was through health workers or as a part of ANC services.
  • 30. 39  Three programs (Nepal, Afghanistan and Zambia) reported the change in facility birth rate in program areas  Programs were not powered to measure a statistically significant change  In these three programs, facility birth rates increasedin the target areas No Adverse Change in Facility Birth Rates
  • 31. 40 Low Incidence of Adverse Outcomes Outcomes # of occurrences (total # of women taking misoprostol at home births) Frequency (Range) Administration Priorto Birth 7 (12 615) 0.06% (0%–0.23%) Total Maternal Deaths 51 (86 732) 0.06% (0%–1.72%) Deaths due to PPH 24 (86 732) 0.03% (0.00%–0.16%) Deaths attributed to misoprostol 0 (86 732) 0% Perceived PPH 194 (72 534) 0.3% (0%–8.9%) Otheradverse outcomes requiring hospital referral 27 (86 732) 0.03% (0%–0.3%)
  • 32. 41  If programs want high coverage, they should design programs with population coverage in mind, considering:  In-home distribution, by CHWs or TBAs, and  Self-administration with adequate education & counseling.  Mistimed self-administration is rare and should not be a reason to limit program development.  Limited available data suggest that programs do not counter national strategies to promote facility-based births. Ourreview suggests that ANC-only distribution achieves 50% less coverage, so it likely does not protect those who need coverage the most. Conclusions forPractice

Hinweis der Redaktion

  1. Introductions from John, Khatidja & Rehana We’re here on behalf of the entire MCHIP Maternal Health Team, led by Jeff Smith. At this roundtable, we’ll be discussing the findings of two recent publications that were led by Jeff Smith and that discuss two key maternal health commodities: magnesium sulfate for the management of pre-clampsia/eclampsia, or PE/E, and misoprostol for the prevention of postpartum hemorrhage, or PPH. We’ll be highlighting the findings that are most relevant for program managers and the steps that programs can take to incorporate these lessons into their work. As you all know, PPH and PE/E continue to be leading causes of maternal mortality in developing countries, so we think it’s helpful to have this forum to discuss them together.
  2. Both of the articles we’re discussing were published earlier this year in BMC Pregnancy and Childbirth . They’re available for free online, and we also have copies available here. Both articles were collaborations with Venture Strategies International, or VSI, in Berkeley, California, and the PE/E article has an author from the Johns Hopkins Bloomberg School of Public Health. Judith Fullerton, a nurse-midwife and independent consultant, is the one who suggested the “integrative review” design. For those who aren’t familiar with “integrative reviews,” they’re similar to systematic reviews in that they use a pre-defined literature search strategy, but they include grey literature in addition to peer-reviewed literature, so they’re a more useful way to find and evaluate operational evidence that isn’t often published in peer-reviewed literature. We’ll talk about each article for approximately 15 minutes and then leave 30 minutes for discussion. John and Khatidja will take the first article, which examines the safety of magnesium sulfate for PE/E. Rehana will take the second article, on community-based distribution of misoprostol for the prevention of PPH at home birth.
  3. As with any drug, we have to balance the risk of side effects with potential benefits. But we also have to have good data on side effects to appropriately estimate risk. This picture depicts a woman suffering from severe pre-eclampsia, and therefore a candidate for magnesium sulfate.
  4. MgSO4 is an anti-convulsant. We have a copy of the 2011 WHO Clinical Guidelines here for anyone who is interested.
  5. This shows countries’ uptake of four maternal health commodities: oxytocin and misoprostol for PPH, and magnesium sulfate and diazepam for severe PE/E. Many countries (those with both green and purple bars above the line) include both MgSO4 and diazepam as their national policy standard for severe PE/E, which creates confusion and resistance among providers who are more comfortable using diazepam, even though magnesium sulfate is the drug of choice. We are working to make magnesium sulfate the sole national standard for PE/E.
  6. These are some common statements we hear about magnesium sulfate in the countries in which we work. Overdose and toxicity is a big concern -- but this can usually be addressed by simply delaying the next scheduled dose. The goal of our review was to systematically identify any data that might support or refute these claims.
  7. From our review of the clinical literature on magnesium sulfate, we knew that these are the potential side effects of magnesium sulfate.
  8. Based on the potential known side effects, we came up with these research questions and designed our literature search strategy around them. We searched for all types of prospective clinical studies where (1) magnesium sulfate was used to manage pre-eclampsia or eclampsia, (2) the study was conducted in a developing country, and (3) the study recorded the incidence of any adverse side effect resulting from magnesium sulfate use.
  9. We included a total of 24 studies, which in the aggregate administered magnesium sulfate to 9556 women and recorded adverse events. This chart presents the overall incidence of five adverse events: affected patella reflex, respiratory depression, oliguria, skipped dose, and calcium gluconate use. As you can see, the incidence of each is extremely low!
  10. There was only one maternal death attributed to magnesium sulfate use among the 9556 women using magnesium sulfate in these 24 studies. There were 90 maternal deaths attributed to other causes. The one attributed death was in a small trial, of a woman who had an extremely elevated serum magnesium level. A large trial with over 5000 participants reported no deaths attributed to magnesium sulfate use.
  11. Taking the incidence rates from the previous slide, we show here the frequency of having one case experiencing these side effects in a hospital that delivers 5000 women annually and where the prevalence of PE/E is 5%, the average global prevalence. Again, these effects are rare. [John to provide explanation of the NNH row if needed.]
  12. To manage the side effects that do occur, a few simple routine monitoring steps can be taken, including a neurologic and respiratory status check and measurement of urinary output. All of these should be performed anyway for patients with severe PE/E! For more serious side effects, magnesium sulfate therapy can be delayed or suspended, or calcium gluconate can be administered.
  13. These picture show a patient with severe PE being monitored.
  14. Our review concluded that magnesium sulfate should be considered a safe drug, with a low incidence of severe side effects and almost no attributable mortality. Side effects can usually be managed by simply delaying the next scheduled dose.
  15. Our findings call for increased awareness of magnesium sulfate as the drug of choice to manage severe PE/E, and for better understanding of the actual incidence of its side effects and ways to best manage them. Clinical leaders and program staff should enable the use of magnesium sulfate as the standard of care for PE/E, a significant cause of maternal mortality.
  16. Specifically reported for 25 study groups. Overall incidence among all 9556 women was 1.3%, with the incidence ranging from 0-8.2%. In the three studies that reported very high incidences of absent patellar reflex, the incidence of respiratory depression was less than 1%.
  17. Use of calcium gluconate reported for 12 of the 34 subject groups. Administered only 17 times, resulting in an overall rate among 9,556 women of less than 0.2%. In one study, Ca gluconate was administered following a dosing error which resulted in administration of 4g of MgSO4 in one hour instead of four hours.
  18. We now turn to the second article, on implementation strategies for community-based distribution of misoprostol for PPH prevention. As you all know, community-based care is essential to reach those women who don’t come to facilities. This review asked the question: what do we know about ways in which misoprostol has been distributed at the community level for the prevention of PPH at home births, which often make up the majority of births in developing countries?
  19. First, a brief primer on PPH. It is very difficult to determine and treat PPH in most clinical settings in developing countries, let alone at home births, so we need PREVENTION .
  20. PPH is the leading cause of maternal mortality—accounting for more than 1/3 of global maternal deaths--and disproportionately affects the developing world. Women in sub-Saharan Africa have a 1 in 39 lifetime risk of dying from pregnancy or childbirth, contrasted with 1 in 3800 in developed countries.
  21. There are two strategies that we know prevent PPH: active management of the third stage of labor and administration of misoprostol immediately after birth. Misoprostol is the only one of the two that is possible without a skilled provider present. It can be distributed before birth and administered either by the women herself or by a person attending the birth, such as a TBA. It’s most commonly distributed as a small package of three sea-blue tablets, each 200mcg for a total dose of 600mcg.
  22. In 2011, WHO reversed its previous position not to include misoprostol on its Model List of Essential Medicines for the prevention of PPH. In 2012, however, the WHO qualified its endorsement of misoprostol for PPH prevention by recommending its administration by CHWs but not by self-administration. The WHO stated that there was insufficient evidence to distribute misoprostol to pregnant women through antenatal care for self-administration at birth. We have a copy of these 2012 WHO Recommendations for anyone interested.
  23. There was also a 2012 Cochrane review that requested more information on misoprostol coverage and adverse outcomes.
  24. MCHIP and VSI were aware of a number of programs that were using community-based distribution of misoprostol both by CHWs and for self-administration at home births. We asked ourselves, what information could we collect and publish about these programs to give WHO and the global community the information they needed to feel comfortable recommending advance distribution of misoprostol for use at home births? We chose these research questions to inform our literature search strategy—only literature that was responsive to at least one of these questions was included in our review. In addition to publishing the integrative review answering these research questions, MCHIP is working closely with WHO to prepare a database of evidence on projects that are predominately using self-administration.
  25. Through our integrative review, we identified 18 studies or programs in 14 separate countries, which had administered misoprostol to more than 86,000 women. Some of those programs were designed to follow up with a small subsample of women to obtain information about use, so we tried to identify the subpopulation of misoprostol users on whom follow-up data was collected and found 12,615 women across these 18 programs.
  26. We found three main types of program design characteristics, what we’ve called “implementation strategies”: the timing of distributing, the person distributing the misoprostol, and the person administering the misoprostol. Some programs used more than one strategy, such as programs that distributed misoprostol at ANC and then, as a catch-all, to women at home birth. This shows the range of timing choices that programs reported using: at any ANC visit after 12 weeks, at a late pregnancy home visit, at a late ANC visit, or at the home birth itself.
  27. This shows the range of cadres that the programs reported using—again, some programs used more than one distribution strategy and cadre, such as health workers at ANC visits and then TBAs at birth.
  28. This shows the range of persons permitted by the program to administer the misoprostol. A majority of the programs allowed self-administration, which gave us useful information responding directly to the WHO’s concerns.
  29. We decided that one way to measure the success of these programs was to determine how well they got misoprostol into the hands of pregnant women or providers who could use it, what we called the “distribution rate,” and also how well they got pregnant women to actually take it, what we called the “coverage rate.” More specifically, we defined the “distribution rate” as the proportion of pregnant women in a program’s catchment area who received misoprostol for PPH prevention. We defined the “coverage rate” as the proportion of women who delivered at home in the catchment area (actual or estimated) who used misoprostol for PPH prevention. As you might expect, a number of the program reports did not contain definite information about these specific numerators and denominators. In fact, only 10 of the 18 programs contained sufficient information to calculate at least one of these two rates. Part of the intent of this review was to suggest the type of data that we think programs should collect so we can build a sufficient evidence base.
  30. When we disaggregated the few distribution and coverage rates that we could collect, we found that distribution by community workers late at home visits late in pregnancy achieved the greatest distribution and coverage. If more programs collected this information, we would have more data points to cross-reference.
  31. One common concern about community-based misoprostol programs is that giving women misoprostol will encourage them to deliver at home and not come to facilities. The programs we reviewed did not contain much concrete data to support or refute that claim, but the three programs that did try to measure a change in facility use among misoprostol users found an increase in facility birth rates in the target areas.
  32. Similar to magnesium sulfate, concerns persist about adverse outcomes in women using misoprostol, so we collected whatever information was available on these outcomes in the program reports. There appears to be a very low incidence of these outcomes, including the PPH that misoprostol is designed to prevent, in women using misoprostol. While there were a total of 51 deaths attributed to misoprostol among the more than 86,000 users, no maternal death was attributed to misoprostol . To the specific concern that women might take the drug at the incorrect time, and particularly taking it before birth occurs, we found that only 7 out of more than 12,000 women, or just 0.06%, reported this happening. Associating those cases with their program implementation strategies, we found that: More cases reported when distributed at any ANC visit compared to home distribution, and More cases when distributed by health worker or ANC provider compared with distribution by any other distributing cadre. Incorrect administration might not be an issue that requires ANC distribution or distribution by a skilled health provider.
  33. Misoprostol is safe and effective for PPH prevention at home births. Programs need to be designed with population coverage in mind and consider using home visits for distribution and allowing self-administration with appropriate education and counseling. Distributing misoprostol at ANC visits only, as the WHO currently recommends, is not likely to achieve the coverage needed to protect women at home births.
  34. We conclude with the story of our first misoprostol client, Alice, this past August in South Sudan, a country with an MMR above 2000. Alice took the 3 misoprostol tablets given to her by an attendant immediately after the delivery of the baby. She explained that she was examined on the abdomen after baby was born and, before delivery of the placenta, swallowed the misoprostol tablets with a glass of water. Alice reported that she experienced coldness, was covered by a blanket for a short time and the coldness disappeared. She had little bleeding which was normal. She is now happy with her baby. We’re continuing to gather evidence to show that community-based distribution of misoprostol works. We encourage all of you who work on misoprostol programs to look at our recommendations for the data that we think should be collected and get this data into the peer-reviewed or grey literature.
  35. If you don’t have time to read the entire articles, we have 2-page briefs with us about each one. You can also find these briefs and other information about our PE/E and PPH programs at www.mchip.net.